Revolution Medicines (RVMD) Director Kim Lorence Sells Shares

What Happened
Director Kim Lorence sold a total of 56,000 shares of Revolution Medicines (RVMD) in open-market transactions on August 31, 2026, generating aggregate proceeds of $11,381,289. The sales were executed in multiple trades at prices reported by lot (weighted averages shown) ranging roughly from $200.56 to $206.15 per share; the overall weighted-average price was about $203.23 per share. These dispositions were made by the Lorence Kim Revocable Trust pursuant to a 10b5-1 trading plan.

Key Details

• Transaction date: 2026-08-31 (filed on Form 4: 2026-09-02). Filing was made within the standard two-business-day Form 4 window.
• Shares sold (by lot): 300 @ $200.56; 6,597 @ $201.47; 12,919 @ $202.48; 26,160 @ $203.55; 7,271 @ $204.35; 2,128 @ $205.19; 625 @ $206.15. Total sold: 56,000 shares for $11,381,289.
• Holdings after sale: The Lorence Kim Revocable Trust held 73,090 shares immediately prior to these sales; after selling 56,000 shares the Trust’s holdings declined to 17,090 shares. The reporting person’s holdings include 1,191 restricted stock units.
• Footnotes of note: Sales executed under a 10b5-1 plan adopted by the Trust on June 1, 2026 (F2). Multiple trades executed at specified price ranges for several lots; weighted-average prices were reported and the filer offers to provide per-trade details on request (F4–F9). The August 2025 transfer of 23,090 shares into the Trust was reported as a form-of-ownership change exempt under Rule 16a-13 (F3).
• Transaction code: S = Sale.

Context
These were open-market sales conducted under a pre-established 10b5-1 plan through the reporting person’s revocable trust. Such sales are commonly routine disposition mechanisms; the filing and footnotes document the trade execution details and prior transfers into the Trust.